TriSalus Life Sciences Inc. (TLSI) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, TriSalus Life Sciences Inc. (NASDAQ: TLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.63 (-1.89% 1D, market cap $227.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TLSI ranks #798 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), TLSI carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 84.6%, and ROIC of -35.0%. By comparison, BDSX (Biodesix Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $245.4M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $208.1M). Among the 5-stock peer group, TLSI leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).
Per TLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826667), TriSalus Life Sciences Inc. generated $45.2M in revenue (+53.4% YoY), -$39.2M in net income, and -$18.9M in free cash flow against $35.3M in total assets and $33.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 84.6% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While TLSI currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.38) and Max Pain ($3.81) forces dealer call-delta covering toward $8.35.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
TriSalus Life Sciences Inc. (TLSI) slipped -1.89% to $3.63, trading at 25% of its 52-week range ($2.2 – $7.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
WESTMINSTER, Colo., October 29, 2026--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform trea
Verano Holdings Corp. (VRNO) delivered earnings and revenue surprises of +50.00% and -1.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +53.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TLSI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TLSI. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, TriSalus Life Sciences Inc. (TLSI) ranks #798 by composite RQD confidence (30/100, grade E) and #553 by equity capitalization ($227.8M). Within this direct 5-issuer industry benchmark cohort, TLSI leads on earnings valuation at N/A trailing P/E, while YDES leads on capital efficiency and profitability with -20.0% ROIC and 28.1% gross margin. YDES currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with TLSI at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TLSI
ACTIVE
TriSalus Life Sciences Inc. | E | 30/100 | — | 84.6% | -35.0% | -1.89% | $227.8M | Benchmark Subject |
| BDSX Biodesix Inc. | D- | 40/100 | — | — | -35.0% | -6.34% | $245.4M | /bdsx-vs-tlsi → |
| XGN Exagen Inc. | D- | 36/100 | — | 58.3% | -35.0% | -2.33% | $208.1M | /xgn-vs-tlsi → |
| YDES YD Bio Limited | D | 44/100 | — | 28.1% | -20.0% | +0.51% | $420.7M | /ydes-vs-tlsi → |
| BNR Burning Rock Biotech Limited | E | 20/100 | — | 74.7% | -35.0% | -7.89% | $115.0M | /bnr-vs-tlsi → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), TriSalus Life Sciences Inc. (TLSI) reported GAAP revenue of $45.2M (+53.4% vs. FY2024 revenue of $29.4M , and +143.9% cumulative change since FY2023) , GAAP net income of -$39.2M, operating cash flow of -$18.0M, and free cash flow of -$18.9M (+54.0% YoY). On the balance sheet, TLSI closed FY2025 with $35.3M in total assets against $33.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $45.2M | -$39.2M | -$18.0M | -$18.9M | $35.3M | $33.0M |
| FY2024 (FY) | 2024-12-31 | $29.4M | -$30.0M | -$40.8M | -$41.2M | $24.0M | $22.1M |
| FY2023 (FY) | 2023-12-31 | $18.5M | -$59.4M | -$50.6M | -$50.6M | — | — |
As of 2026-11-03, TriSalus Life Sciences Inc. (NASDAQ: TLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.63 (-1.89% 1D, market cap $227.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TLSI ranks #798 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), TLSI carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 84.6%, and ROIC of -35.0%. By comparison, BDSX (Biodesix Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $245.4M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $208.1M). Among the 5-stock peer group, TLSI leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).
Per TLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826667), TriSalus Life Sciences Inc. generated $45.2M in revenue (+53.4% YoY), -$39.2M in net income, and -$18.9M in free cash flow against $35.3M in total assets and $33.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
TLSI last traded at $3.63 (-1.89% on volume of 230,913 shares), positioning the stock -17.12% below its 50-day simple moving average ($4.38) and -17.12% below its 200-day simple moving average ($4.38). Across its 52-week range of $2.20 to $7.95, TLSI sits at the 24.9% percentile with a 14-day RSI of 40.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($3.21 to $4.05).
TriSalus Life Sciences Inc. (TLSI) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.63 (-1.89% 1D, market capitalization $227.8M).
TriSalus Life Sciences Inc. Is listed on NASDAQ under ticker TLSI and is classified in the Health Care sector, Medical Specialities industry. Revenue reported for FY 2025 is $45.2M, . The business profile in the source data is limited to sector and market classification.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), TriSalus Life Sciences Inc. (TLSI) reported $45.2M in annual revenue (up from $29.4M in FY2024, +53.4% YoY) and -$39.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($18.5M revenue, -$59.4M net income) through FY2025, TLSI scaled operating cash flow to -$18.0M and free cash flow to -$18.9M, backed by $35.3M in total assets against $33.0M in total debt.
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The only sector context available is the Health Care / Medical Specialities classification. An investor should treat this section as an absence of mapped ripple effects rather than evidence that none exist.
Real-time company headlines, analyst actions, and sector developments for TriSalus Life Sciences Inc. (TLSI) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering TriSalus Life Sciences Inc. (TLSI) market action, institutional positioning, and fundamental catalysts.
Long TLSI at $3.70 targeting $4.44. Revenue grew from $18.5M to $45.2M over FY 2023 to FY 2025 while operating losses narrowed from -$54.5M to -$26.9M.. Institutional whale score is 3/20 and the risk/reward vs. the $2.20 52-week low is skewed heavily in favor of bulls.
Both sides have a point here — TLSI's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Fading this rally in TLSI at $3.70. ROIC of -35% and FCF of -$18.9M in FY 2025 show the business is still consuming cash with an RQD score of 31 and E grade.. With a beta of 1.0 and the stock sitting at $3.70 (52-wk range $2.20–$7.95), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: